Aspirin’s effects on CRCs with the PIK3CA mutation are a hot research topic [48], with results from an RCT that examined disease-free survival in CRC patients diagnosed at stages II–III, finding a clear trend towards improved survival in aspirin users [49]. This evidence concerns the gene PIK3CA and colorectal carcinoma.